<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076180</url>
  </required_header>
  <id_info>
    <org_study_id>040089</org_study_id>
    <secondary_id>04-C-0089</secondary_id>
    <nct_id>NCT00076180</nct_id>
    <nct_alias>NCT00079196</nct_alias>
  </id_info>
  <brief_title>Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia</brief_title>
  <official_title>Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the use of the humanized Mik-beta-1 (Hu-Mik-beta1) antibody in&#xD;
      patients with T-cell large granular lymphocytic leukemia (T-LGL). Patients with T-LGL often&#xD;
      have reduced white blood cells, red blood cells, and platelets, and increased numbers of&#xD;
      abnormal cells called large granular lymphocytes (LGLs). Patients may have recurrent&#xD;
      infections, anemia, or abnormal bleeding. Hu-Mik-beta1 attaches to LGL cells and blocks the&#xD;
      action of growth factors called interleukins that stimulate LGL growth. Blocking these&#xD;
      interleukins may stop T-LGL leukemia cells from growing. This study will determine the dose&#xD;
      and frequency of treatment with Hu-Mik-(SqrRoot) 1 that can safely be given to patients to&#xD;
      coat the surface of their leukemic cells with antibody, determine how long the antibody lasts&#xD;
      in the blood after injection, and examine the side effects and possible benefits of the drug&#xD;
      in these patients.&#xD;
&#xD;
      Patients age 18 or older with T-LGL may be eligible for this study. Candidates will be&#xD;
      screened with a medical history and physical examination, review of pathology studies, skin&#xD;
      biopsy, evaluation of rheumatoid arthritis if present, chest x-ray, computerized tomography&#xD;
      (CT) scans and other imaging studies as needed, bone marrow biopsy, and blood and urine&#xD;
      tests.&#xD;
&#xD;
      Participants will receive a single dose of Hu-Mik-beta1 by a 90-minute infusion through a&#xD;
      vein. Groups of patients will be treated with increasing doses (0.5, 1.0, and 1.5 mg/kg) of&#xD;
      the antibody. Patients who develop serious drug side effects are taken off the study. The&#xD;
      treatment requires a 3- to 4-day hospital stay. In addition to Hu-Mik-(SqrRoot) 1 treatment,&#xD;
      patients will undergo the following tests and procedures:&#xD;
&#xD;
        -  Collection of blood for 8 days following the dose of Hu-Mik-beta1 to measure blood&#xD;
           levels of the antibody.&#xD;
&#xD;
        -  Follow-up visits of 1 to 2 days at 22, 29, and 43 days after the dose of the antibody&#xD;
           and then every 3 months for a total of 9 months.&#xD;
&#xD;
        -  Bone marrow aspirate and biopsy if one has not been done within 6 weeks before entering&#xD;
           the study, and a repeat biopsy if complete remission of T-LGL is achieved after&#xD;
           completing treatment. For the biopsy, an area of the hip is numbed and a special needle&#xD;
           is used to draw bone marrow from the hipbone.&#xD;
&#xD;
        -  Imaging studies, such as chest x-ray and CT scan of the body after completing treatment&#xD;
           if the screening scans showed abnormalities due to the T-LGL leukemia.&#xD;
&#xD;
        -  Lymph node biopsy in individuals with enlarged superficial lymph nodes due to T-LGL&#xD;
           leukemia to see if the treatment is reaching the leukemia in the lymph nodes.&#xD;
&#xD;
      There may or may not be a direct benefit from participating in this study. However, the&#xD;
      results may help in the treatment of future patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  T cell large granular lymphocyte (T-LGL) leukemia is a chronic lymphoproliferative&#xD;
           disorder associated with granulocytopenia, anemia and/or thrombocytopenia.&#xD;
&#xD;
        -  Although agents such as cyclosporine and methotrexate have shown activity in T-LGL,&#xD;
           treatment of T-LGL has remained largely undefined and symptomatic.&#xD;
&#xD;
        -  The shared IL-2R/Il-15R Beta receptor (CD122) is over expressed on T-LGL cells and may&#xD;
           stimulate growth T-LGL cells through its interaction with IL-15.&#xD;
&#xD;
        -  Hu-Mik-Beta1 is a humanized monoclonal antibody that binds to IL-2R/IL-15R Beta&#xD;
&#xD;
        -  Hu-Mik-Beta1 may inhibit the growth and exert cytotoxic activity against T-LGL cells.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of&#xD;
           Hu-Mik-Beta1 when administered to patients with T-LGL.&#xD;
&#xD;
        -  To determine the dose of Hu-Mik-Beta1 required to saturate IL-2R/IL-15R Beta (CD122) on&#xD;
           -T-LGL cells in the peripheral blood.&#xD;
&#xD;
        -  To determine the pharmacokinetics and serum die-away curve of Hu-Mik-Beta1.&#xD;
&#xD;
        -  To provide preliminary information on the clinical response following single dose&#xD;
           administration of Hu-MiK-Beta1 in patients with CD122 expressing T-LGL leukemia.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      --T cell large granular lymphocyte leukemia (T-LGL).&#xD;
&#xD;
      Patients must have a granulocyte count of less than 1000/microL, or hemoglobin less than 10&#xD;
      gm/dL, or be transfusion dependent, or platelets less than 100,000/ microL, or any&#xD;
      combination of these unless receiving a hematopoietic growth factor.&#xD;
&#xD;
        -  T-LGL cell count greater than or equal to 1000/microL (CD3 plus/CD8 plus/usually CD57&#xD;
           plus) by flow cytometry.&#xD;
&#xD;
        -  Patients may be receiving a stable dose of a hematopoietic growth factor.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Cohorts of 3 patients each will be treated with a single intravenous dose of&#xD;
           Hu-Mik-Beta1 at 0.5, 1.0 or 1.5 mg/kg.&#xD;
&#xD;
        -  Patients will be observed for adverse events for 6-weeks.&#xD;
&#xD;
        -  Detailed pharmacokinetic studies and determination of CD122 receptor saturation will be&#xD;
           performed.&#xD;
&#xD;
        -  Response will be evaluated using hematological, flow cytometry, molecular and clinical&#xD;
           evaluations.&#xD;
&#xD;
        -  An additional 3 patients will be accrued at the highest dose or MTD to aid in design of&#xD;
           a Phase II trial.&#xD;
&#xD;
        -  Patients participating in Phase I will also be eligible to participate in Phase II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1, 2004</start_date>
  <completion_date type="Actual">January 9, 2019</completion_date>
  <primary_completion_date type="Actual">November 12, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT and MTD of Hu MIK Beta 1</measure>
    <time_frame>21 days</time_frame>
    <description>Adverse events will be tabulated/reported by type, grade, and frequency.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>T-Cell Large Granular Lymphocytic Leukemia</condition>
  <condition>Leukemia, T-Cell Large Granular Lymphocytic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Hu-MiK Beta-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hu-MiK-Beta-1</intervention_name>
    <description>Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
        All patients must have histologically or cytologically confirmed T-LGL leukemia as defined&#xD;
        by:&#xD;
&#xD;
        i. A peripheral blood smear or bone marrow biopsy/aspirate with morphological findings&#xD;
        consistent with LGL as determined by Hematopathology section, the NIH Clinical Center, or&#xD;
        the Laboratory of Pathology, NCI, and;&#xD;
&#xD;
        ii. An absolute C3+, CD8+, usually CD57+ cell (T-LGL) count greater than or equal to&#xD;
        1000/uL in the peripheral blood or bone marrow as measured by flow cytometry.&#xD;
&#xD;
        iii. At least 50% of the CD3+/CD8+ cells must also express CD122 (IL-2/15RB plus).&#xD;
&#xD;
        iv. Clonal T cell receptor (TcR) rearrangement while desirable, is not a requirement for&#xD;
        eligibility. TcR rearrangement may be determined by Southern blotting or polymerase chain&#xD;
        reaction (PCR).&#xD;
&#xD;
        Patients must have T-LGL-associated hemocytopenia(s)* as defined by an absolute granulocyte&#xD;
        count (AGC) less than 1000/uL, platelet count less than100,000/uL or hemoglobin less than&#xD;
        9.0 gm/dL, or have required transfusion of 3 or more units of red blood cell products in&#xD;
        the last 6 months, or any combination of these.&#xD;
&#xD;
        *Patients being treated with a stable dose of hemopoietic growth factors for greater than&#xD;
        4-weeks whose peripheral blood counts exceed these values are eligible for the study. A&#xD;
        stable dose of a hematopoeitic growth factor(s) may be continued while the patient is on&#xD;
        the study.&#xD;
&#xD;
        Patients requiring antibiotic or treatment with antiviral drugs on more than two occasions&#xD;
        over the previous 12 months for bacterial or viral infections associated with their LGL are&#xD;
        eligible.&#xD;
&#xD;
        Patients must be greater than or equal to 18 years of age.&#xD;
&#xD;
        Untreated patients as well as those previously treated with cyclosporine A (CsA),&#xD;
        chemotherapy, corticosteroids, interferon, erythropoietin, IL-11, G-CSF or GM-CSF, murine&#xD;
        MiK-Beta-1 (or having undergone splenectomy are eligible for study.&#xD;
&#xD;
        Omission of cyclosporine A, chemotherapy and interferon is required for at least 4 weeks&#xD;
        prior to entry onto the trial. Patients on stable doses (greater than 4 weeks) of&#xD;
        commercial erythropoietin, G-CSF, GM-CSF or IL-11 products are eligible for the study.&#xD;
        Patients receiving corticosteroids will not be excluded. Patients receiving corticosteroids&#xD;
        must be on a stable dose of prednisone (less than 25 mg/day) or equivalent dose steroid for&#xD;
        at least 3 weeks before receiving MiK-B -1 on the study.&#xD;
&#xD;
        Patients must have normal renal function (serum creatinine less than or equal to 1.5 mg/dL)&#xD;
        and hepatic function (bilirubin less than or equal to 2.0 mg/dL, SGOT, SGPT less than or&#xD;
        equal to 2.5 fold greater than the upper limit of normal).&#xD;
&#xD;
        Patients must have a Karnofsky performance status of greater than or equal to 70%.&#xD;
&#xD;
        Patients must have a life expectancy greater than 2 months.&#xD;
&#xD;
        Patients must be able to understand and sign the Informed Consent Document.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Patients must have none of the following at the time of enrollment:&#xD;
&#xD;
        Symptomatic central nervous system (CNS) involvement with LGL leukemia.&#xD;
&#xD;
        Pregnant or actively nursing patients are ineligible. The effects of Hu-MiK-Beta-1 on the&#xD;
        developing fetus and nursing infant are unknown. Female patients of childbearing potential&#xD;
        will be tested for pregnancy within 72 hours of initiating the study.&#xD;
&#xD;
        Patients with CTC grade 4 granulocytopenia or anemia.&#xD;
&#xD;
        Patients requiring platelet transfusions in the preceding 12-months for platelet counts of&#xD;
        less than or equal to 10,000/mm(3) or spontaneous bleeding episodes.&#xD;
&#xD;
        Patients testing positive for the human immunodeficiency virus (HIV) or human T cell&#xD;
        lymphotrophic virus (HTLV-I/II) are ineligible, because the toxicity may be different in&#xD;
        this population.&#xD;
&#xD;
        Patients testing positive for hepatitis B virus surface antigen (HbsAg) or antibodies to&#xD;
        hepatitis C virus are ineligible because Hu-MiK-Beta-1 therapy might be associated with&#xD;
        increased viral replication.&#xD;
&#xD;
        Patients receiving prior therapy with murine MiK-Beta-1 that have developed human&#xD;
        anti-mouse (HAMA) or human anti-human (HAHA) antibodies, or that have experienced CTC grade&#xD;
        III or greater toxicity attributable to the antibody are ineligible.&#xD;
&#xD;
        Patients with a prior history of a Grade III or greater allergic reaction related to a&#xD;
        previously administered humanized monoclonal antibody are ineligible.&#xD;
&#xD;
        Patients with other serious concurrent medical conditions (e.g., acute myocardial&#xD;
        infarction within 6 months, unstable angina, NYHA Class II/IV congestive heart failure,&#xD;
        respiratory insufficiency requiring oxygen therapy, uncontrolled hypertension, symptomatic&#xD;
        cerebrovascular disease or stroke within 6 months, receiving immunosuppression for an organ&#xD;
        graft, etc.) that may otherwise limit their survival are not eligible.&#xD;
&#xD;
        Other malignancy within five years, unless the probability of recurrence of the prior&#xD;
        malignancy is less than or equal to 10 percent at 5-years. Patient's curatively treated for&#xD;
        squamous cell carcinoma and basal cell carcinoma of the skin and carcinoma in situ of the&#xD;
        uterine cervix (CIN) or patients with a history of malignant tumor in the past that have&#xD;
        been disease free for at least five years are also eligible for this study.&#xD;
&#xD;
        Patients with serious active infection requiring systemic anti-infective therapy.&#xD;
&#xD;
        Any physical or psychological condition that would preclude drug administration or patient&#xD;
        compliance with the protocol or that in the opinion of the investigator may pose an&#xD;
        additional risk in administering the study drug to the patient or that would not permit the&#xD;
        patient to complete the study or give Informed Consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Waldmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>KÃ¶hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495-7.</citation>
    <PMID>1172191</PMID>
  </reference>
  <reference>
    <citation>Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986 May 29-Jun 4;321(6069):522-5.</citation>
    <PMID>3713831</PMID>
  </reference>
  <reference>
    <citation>Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657-62. Review.</citation>
    <PMID>2047874</PMID>
  </reference>
  <verification_date>January 9, 2019</verification_date>
  <study_first_submitted>January 14, 2004</study_first_submitted>
  <study_first_submitted_qc>January 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2004</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <keyword>cytotoxic activity against T-LGL cells</keyword>
  <keyword>chronic lymphoproliferative disorder</keyword>
  <keyword>T-LGL Leukemia</keyword>
  <keyword>Natural Killer Cells</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphocytic Leukemia</keyword>
  <keyword>T-LGL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

